|本期目录/Table of Contents|

[1]陈雨秋,周国华,顾军.半乳糖凝集素3与乳腺癌的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2020,22(5):510-515.[doi:10.3969/j.issn.1672-271X.2020.05.013]
　CHEN Yu-qiu,ZHOU Guo-hua,GU Jun.Research progress of galectin-3 and breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2020,22(5):510-515.[doi:10.3969/j.issn.1672-271X.2020.05.013]
点击复制

半乳糖凝集素3与乳腺癌的研究进展()
分享到62.8K

《医学研究与战创伤救治》（原医学研究生学报）[ISSN:1672-271X/CN:32-1713/R]

卷:
第22卷
期数:
2020年5期
页码:
510-515
栏目:
综述
出版日期:
2020-09-09

文章信息/Info

Title:
Research progress of galectin-3 and breast cancer
作者:
陈雨秋; 周国华; 顾军
作者单位：210002南京，南京大学医学院附属金陵医院（东部战区总医院）全军普通外科研究所（陈雨秋、顾军），临床药理科（周国华）
Author(s):
CHEN Yu-qiu1 ;  ZHOU Guo-hua2;  GU Jun1
(1.Research Institute of General Surgery, 2. Clinical Pharmacology, Jingling Hospital, Nanjing University School of Medicine/General Hospital of Eastern Theater Command, PLA, Nanjing 210002, Jiangsu, China)
关键词:
乳腺癌; 半乳糖凝集素3; 预后; 转移
Keywords:
breast cancer;  galectin-3;  prognosis;  metastasis
分类号:
R737.9
DOI:
10.3969/j.issn.1672-271X.2020.05.013
文献标志码:
A
摘要:
半乳糖凝集素3（Gal-3）是糖粘合蛋白家族的一员，在多种肿瘤的发生、进展、侵袭和转移中起重要作用。Gal-3的过表达增强了肿瘤细胞的活性、侵袭性，并且抑制细胞的凋亡，促进血管生成并诱导肿瘤免疫逃逸。文章主要就乳腺癌诊断、预后、治疗、转移等方面对Gal-3与乳腺癌相关性进行综述。
Abstract:
Galectin-3 is a member of glycobinding protein family, which plays an important role in the tumor occurrence，progression, invasion and metastasis. The overexpression of galectin-3 enhances the activity and invasiveness of cancer cells, and inhibits the apoptosis of breast cancer cells. Also, it promotes angiogenesis and induces tumor immune escape. In this paper, we discuss the relationship between galectin-3 and breast cancer in diagnosis, prognosis, treatment and metastasis of breast cancer.

参考文献/References:

[1]Nangia-Makker P, Wang Y, Raz T, et al. Cleavage of galectin-3 by matrix metalloproteases induces angiogenesis in breast cancer[J]. Int J Cancer, 2010, 127(11):2530-2541.
[2]Radosavljevic G, Jovanovic I, Majstorovic I, et al. Deletion of Gal-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity[J]. Clin Exp Metastasis, 2011, 28(5):451-462.
[3]Prieto VG, Mourad-Zeidan AA, Melnikova V, et al. Galectin-3 Expression Is Associated with Tumor Progression and Pattern of Sun Exposure in Melanoma[J]. Clin Can Res, 2006, 12(22):6709.
[4]Funasaka T, Raz A, Nangia-Makker P . Nuclear transport of galectin-3 and its therapeutic implications[J]. Semi Can Biol, 2014, 27:30-38.
[5]Haudek KC, Spronk KJ, Voss PG, et al. Dynamics of galectin-3 in the nucleus and cytoplasm[J]. Bio Biophys Acta, 2010, 1800(2):181-189.
[6]Fortuna-Costa A, Gomes AM, Kozlowski EO, et al. Extracellular Galectin-3 in Tumor Progression and Metastasis[J]. Front Oncol, 2014, 4:138.
[7]Xin M, Dong XW, Guo XL. Role of the interaction between galectin-3 and cell adhesion molecules in cancer metastasis[J]. Biom Pharmacother, 2015, 69:179-185.
[8]Smetana K, André S, Kaltner H, et al. Context-dependent multifunctionality of galectin-1: a challenge for defining the lectin as therapeutic target[J]. Exp Opin Ther Targ, 2013, 17(4):379-392.
[9]Farnworth SL, Henderson NC, Mackinnon AC, et al. Galectin-3 reduces the severity of pneumococcal pneumonia by augmenting neutrophil function[J]. Am J Pathol, 2008, 172(2): 395-405.
[10]Mackinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3[J]. J Immunol, 2008, 180(4): 2650-2658.
[11]Cecchinelli B, Lavra L, Rinaldo C, et al. Repression of the antiapoptotic molecule Gal-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis[J]. Mol Cell Biol, 2006, 26(3): 4746-4757.
[12]Harazono Y, Nakajima K, Raz A. Why anti-Bcl-2 clinical trials fail: a solution[J]. Cancer Metastasis Rev, 2014, 33(1):285-294.
[13]Harazono Y, Kho DH, Balan V, et al. Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells[J]. Oncotarget, 2014, 5(20):9992-10001.
[14]Demotte N, Wiers G, Smissen, P, et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice[J]. Cancer Res, 2010, 70(19):7476-7488.
[15]Gordon-Alonso M, Hirsch T, Wildmann C, et al. Galectin-3 captures interferon-gamma in the tumor matrix reducing chemokine gradient production and T-cell tumor infiltration[J]. Nature Commu, 2017, 8(1):793.
[16]Tanida S, Mori Y, Ishida A, et al. Galectin-3 binds to MUC1-N-terminal domain and triggers recruitment of β-catenin in MUC1-expressing mouse 3T3 cells[J]. Biochim Biophys Acta, 2014, 1840(6):1790-1797.
[17]Zhao W, Ajani JA, Sushovan G, et al. Galectin-3 Mediates Tumor Cell-Stroma Interactions by Activating Pancreatic Stellate Cells to Produce Cytokines via Integrin Signaling[J]. Gastroenterology, 2018, 154(5):1524-1537.
[18]Dash P, Minz AP, Senapati S. Possible Autocrine Function of Galectin-3 in Pancreatic Stellate Cells.[J].Gastroenterology,2018,155(3):933-934.
[19]Kariya Y, Oyama M, Hashimoto Y, et al. β4-Integrin/PI3K Signaling Promotes Tumor Progression through the Galectin-3-N-Glycan Complex[J]. Mol Cancer Res, 2018, 16(6):1024-1034.
[20]Boscher C, Zheng YZ, Lakshminarayan R, et al. Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells[J]. J Biol Chem, 2012, 287(39):32940-32952.
[21]Shirakawa K, Endo J, Kataoka M, et al. IL (Interleukin)-10-STAT3-Galectin-3 Axis Is Essential for Osteopontin-Producing Reparative Macrophage Polarization After Myocardial Infarction[J]. Circulation, 2018, 138(18):2021-2035.
[22]Song L, Tang JW, Owusu L, et al. Galectin-3 in cancer[J]. Clinica Chimica Acta, 2014, 431(3):185-191.
[23]Bartolazzi A, Orlandi F, Saggiorato E, et al. Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study.[J]. Lancet Oncol, 2008, 9(6):543-549.
[24]Matos LL, Del Giglio AB, Matsubayashi CO, et al. Expression of CK-19, galectin-3 and HBME-1 in the differentiation of thyroid lesions: systematic review and diagnostic meta-analysis[J]. Diagn Pathol, 2012, 7:97.
[25]Arnal-Estape A, Nguyen DX. Sweets for a Bitter End: Lung Cancer Cell-Surface Protein Glycosylation Mediates Metastatic Colonization[J]. Cancer Dis, 2015, 5(2):109-111.
[26]Seguin L, Camargo MF, Wettersten HI, et al. Galectin-3, a Druggable Vulnerability for KRAS-Addicted Cancers[J]. Cancer Discov, 2017, 7(12):1464-1479.
[27]Nakajima K, Kho DH, Yanagawa T, et al. Galectin-3 inhibits osteoblast differentiation through notch signaling[J]. Neoplasia, 2014, 16(11):939-949.
[28]陈涛，王璇，程凯，等. CD47在乳腺癌及癌旁组织中的表达及其意义[J].东南国防医药,2018,20(5):501-505.
[29]Zuo X, Chen L, Liu L, et al. Identification of a panel of complex autoantigens (LGALS3, PHB2, MUC1, and GK2) in combination with CA15-3 for the diagnosis of early-stage breast cancer[J]. Tumour Biol, 2016, 37(1):1309-1317.
[30]周洁，陈钰，陈道桢.三阴性乳腺癌的治疗现状与进展[J].医学研究生学报，2018,31(8):853-858.
[31]许涛，杨军，韩咏，等. 基于单细胞测序分析三阴性乳腺癌中巨噬细胞标记基因及其功能[J].医学研究生学报，2020,33(7):715-719.
[32]Zhang H, Luo M, Liang X, et al. Galectin-3 as a marker and potential therapeutic target in breast cancer[J]. PLoS One, 2014, 9(9):e103482.
[33]Liu XH, Deng CX, Hu PC, et al. Functional impact of Galectin-3 and TRAIL expression in breast cancer cells.[J]. Eur Rev Med Pharmacol, 2017, 21(16):3626-3633.
[34]Ilme M, Mazurek N, Gilcrease M, et al. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells[J]. Breast Cancer Res, 2016, 18(1):97.
[36]Piyush T, Chacko AR, Sindrewicz P, et al. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells[J]. Cell Death Differ, 2017, 24(11):1937-1947.
[37]Boscher C, Zheng YZ, Lakshminarayan R, et al. Galectin-3 Protein Regulates Mobility of N-cadherin and GM1 Ganglioside at Cell-Cell Junctions of Mammary Carcinoma Cells[J]. J Biol Chem, 2012, 287(39):32940-32952.
[38]Lin TW, Chang HT, Chen CH, et al. Galectin-3 Binding Protein and Galectin-1 Interaction in Breast Cancer Cell Aggregation and Metastasis[J]. J Am Chem Soc, 2015, 137(30):9685-9693.
[39]Mammadova-Bach E, Gil-Pulido J, Sarukhanyan E, et al. Platelet glycoprotein VI promotes metastasis through interaction with cancer cell-derived Galectin-3[J].Blood, 2020, 135(14):1146-1160.
[40]Topcu T O, Kavgaci H, Gunaldi M, et al. The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis[J]. J Cancer Res Ther, 2018, 14(Supplement):S583-S586.
[41]Murugaesu N, Iravani M, van Weverwijk A, et al. An in vivo functional screen identifies ST6GalNAc2 sialyltransferase as a breast cancer metastasis suppressor[J]. Cancer Discov, 2014, 4(3):304-317.
[42]Boutas I, Potiris A, Brenner W, et al. The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature[J]. Arch Gynecol Obstet, 2019, 300(5):1113-1120.
[43]Barrow H, Guo X, Wandall HH, et al. Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium[J]. Clin Cancer Res, 2011, 17(22):7035-7046.
[44]Rodriguez-Barrueco R, Nekritz EA, Bertucci F, et al. miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy[J]. Genes Dev, 2017, 31(6):553-566.
[45]Piyush T, Chacko AR, Sindrewicz P, et al. Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells[J]. Cell Death Different, 2017, 24(11):1937-1947.
[46]Harazono Y, Kho DH, Balan V, et al. Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling[J]. Oncotarget, 2015, 6(23):19592-19604.
[47]Cai GQ, Ma XD, Chen BL, et al. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation[J]. Tumour Biol, 2016, 37(9):11883-11891.

相似文献/References:

[1]邵明永,丁庆莉,高 纯,等.CA125和CA153联合检测对乳腺癌的诊治价值[J].医学研究与战创伤救治(原医学研究生学报),2013,15(05):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
　SHAO Ming-yong,DING Qing-li,GAO Chun,et al.Roles of detection of CA125 and CA153 in diagnosis and therapy of breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(5):433.[doi:10.3969/j.issn.1672-271X.2013.05.001]
[2]蒋 静,程珠玲.乳腺肿瘤患者心理护理的对策[J].医学研究与战创伤救治(原医学研究生学报),2011,13(06):553.
[3]杜庆安,丁蓉蓉,蔡 凯,等.HER-2多肽负载自体树突状细胞治疗HER-2阳性乳腺癌的初步研究[J].医学研究与战创伤救治(原医学研究生学报),2013,15(06):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
　DU Qing-an,DING Rong-rong,CAI Kai,et al.The primary effect of vaccination with autologous dendritic cells loaded with Her-2 peptides against Her-2 positive breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2013,15(5):581.[doi:10.3969/j.issn.1672-271X.2013.06.009]
[4]朱成宾,潘玉琴,何帮顺.微小RNA多态性与中国女性人群乳腺癌发病及病理特征的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(01):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
　ZHU Cheng-bin,PAN Yu-qin,HE Bang-shun..Study on the association of polymorphisms in microRNAs and risk of breast cancer and its clinic pathological parameters[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(5):22.[doi:10.3969/j.issn.1672-271X.2015.01.007]
[5]刘 彧,童清平,连 娟,等.乳腺癌弹性超声特征与分子生物学指标的相关性研究[J].医学研究与战创伤救治(原医学研究生学报),2015,17(02):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
　LIU Yu,TONG Qing-ping,LIAN Juan,et al.Relationship between ultrasonic elastography features and ER， PR， Her-2 and Ki67 expression in molecular biology of breast[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2015,17(5):116.[doi:10.3969/j.issn.1672-271X.2015.02.002]
[6]纪军生,陆云峰,赵亚萍.甲状腺微小癌Galectin-3、CK19、CD56及TPO蛋白表达分析[J].医学研究与战创伤救治(原医学研究生学报),2016,18(03):303.[doi:10.3969/j.issn.1672-271X.2016.03.024]
[7]陈涛,王璇,程凯,等.CD47在乳腺癌及癌旁组织中的表达及其意义[J].医学研究与战创伤救治(原医学研究生学报),2018,20(05):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
　CHEN Tao,WANG Xuan,CHENG Kai,et al.Expression and significance of CD47 in breast cancer and pericancerous tissues[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2018,20(5):501.[doi:10.3969/j.issn.1672-271X.2018.05.012]
[8]地里呼玛尔·吐鲁洪,李欣芳,王少华.HR+/HER2-乳腺癌内分泌治疗的研究进展[J].医学研究与战创伤救治(原医学研究生学报),2021,23(04):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
　Dilihumaer Tuluhong,LI Xin-fang,WANG Shao-hua.The trend of endocrine therapeutic approach in HR+/HER2-breast cancer[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2021,23(5):387.[doi:10.3969/j.issn.1672-271X.2021.04.011]
[9]何小芳,周敏,熊朝月,等.乳腺癌超声征象及其术后复发的危险因素分析[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
　HE Xiao-fang,ZHOU Min,XIONG Chao-yue,et al.Ultrasonicsigns of breast cancer and analysis of risk factors for postoperative recurrence[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(5):274.[doi:10.3969/j.issn.1672-271X.2022.03.011]
[10]吴勤研,蓝晓红,吴波,等.基于生物信息技术分析人参皂苷防治乳腺癌的作用机制[J].医学研究与战创伤救治(原医学研究生学报),2022,24(3):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]
　WU Qin-yan,LAN Xiao-hong,WU Bo,et al.Analysis of the mechanism of action of ginsenosides in preventing and treating breast cancer based on bioinformatics technology[J].JOURNAL OF MEDICALRESEARCH —COMBAT TRAUMA CARE,2022,24(5):282.[doi:10.3969/j.issn.1672-271X.2022.03.013]

备注/Memo

备注/Memo:
基金项目：江苏省科技项目（BE2017726）
更新日期/Last Update: 2020-09-09